9 / 20
Page 32
&
24
th
Biotechnology Congress: Research & Innovations
CRISPR Cas9 Technology and Genetic Engineering
Annual Congress on
October 24-25, 2018 | Boston, USA
Journal of Biotechnology & Biomaterials | ISSN: 2155-952X | Volume: 8
Effect of glycosylation and physico-chemical properties on biological activity of anti-HER2 molecule
Sourav Majumdar, Jayachandran Ramalingama
and
Sunil Gairolaa
Serum institute of India Pvt Ltd Pune, India
Background:
The biological activity of an anti-HER2 molecule is profoundly influenced by the microheterogeneity of the
N-linked glycan profile. A minor change in glycan profile of anti-HER2 molecule during post-translational modification
showed an impact on its biological activity, Pharmacokinetics (PK) as well as the stability of the molecule. The complexities in
glycan pattern of anti-HER2 molecule further encourage the need of new analytical challenges in evaluating the comparability
with innovator molecule in recent scenario.
Aim/Objective:
A comparison of glycan profiling and binding kinetics including charge variant heterogeneity analysis of anti-
HER2 molecule with innovator molecule was aimed for the current investigation.
Methodology:
In the current investigation, The PNGase F digestion of anti-HER2 molecule followed by UPLC analysis
under Normal phase liquid chromatographic conditions using a platform approach to establish the chromatographic profile
of various Glycan residues such as G0, G0F, GIFa and GIFb, G2F. Further, binding with the HER2 receptor under
in vitro
conditions through Biocore T200 analysis was evaluated to demonstrate the binding kinetics. Additionally, charge variant
heterogeneity was subjected as a part of extensive characterization to evaluate the anti-HER2 molecule in comparison with
innovator molecule.
Results and Discussion:
Anti-HER2 molecule with a mass of 148kDa was purified and a comparison against innovator
molecule in glycan profiling was identified by predominant residues, which represent 90% of the glycosylation profile of the
anti-HER2 molecule. The terminal galactosylation and fucosylation of glycan residues influence the CDC and ADCC activity,
respectively. The variability in the glycan profile can thus affect the biological activity. Further, the high mannose content in
anti-HER2 molecule showed the early clearance and provides a strong impact on its PK. Additionally, binding with a HER2
receptor under
in vitro
conditions through Biocore T200 analysis was evaluated to demonstrate the binding kinetics. The
dynamic binding nature of anti-HER2 molecule (6.21x10
-10
M) and innovator molecule (6.95x10
-10
M) showed the closeness
of KD value. Moreover, the weak binding of acidic variants with HER2 receptor also provides an impact on ADCC activity
and hence, charge variant analysis was shown to be equally important to demonstrate the efficacy of the anti-HER2 molecule.
Acidic variant (K0, deamidated Asn) and basic variants (K1, K2) were determined by cation exchange chromatography (CEX)
and percentage of acidic variant (<35%) were evaluated based on separation on cation exchange column in UHPLC system. The
comparisons were carried out based on the response of reference standard peaks under the identical condition and determine
the percentage of acidic variants.
Conclusion:
Overall, the efficacy and comparability aspects of the in-house anti-HER2 molecule were evaluated against the
innovator’s molecule and attested its candidature as a “Biosimilar” in the pharmaceutical therapeutic domain.
Biography
Sourav Majumdar serves as a Deputy Manager in Serum Institute of India Pvt. Ltd, Pune. He has developed his core expertise in the area of Bioanalytical method
development in proteomics platform. He is leading the group of biosimilar especially dealing with recombinant monoclonal antibody. After completion of his PhD
degree he joined EPR Centre for cancer research, Hyderabad as ADL lead. He developed several analytical methods for routine and extensive characterization of
mAb molecule. Formerly, he worked in Intas Bio Pharmaceutical R&D stability division as Senior Research Associate. He then joined for USV and was assigned
to work on various recombinants Biosimilar Therapeutics with several analytical challenges especially with anticancer molecule. He joined as a Junior Research
fellow in MBBT department for PhD His research was on a “Novel Fibrinolytic Enzyme and a comparison with commercially available Cardiovascular Drugs under
in vitro
and
in vivo
conditions”. He has his majors in Bio-Chemistry from University of Pune, 2004. He is a recipient of “National Level fellowship” and “Ratan Tata
fellowship”. He was awarded the best speaker from Garware Chemical Association. He published a series of Research Article in reputed International Journals.
sourav.majumdar1978@gmail.comSourav Majumdar et al., J Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C4-097